Almirall SA (BME: ALM), a Spain-based global biopharmaceutical company, announced on Monday that it has received approval from the European Commission for its Klisyri (tirbanibulin) intended for the topical treatment of actinic keratosis, a precancerous skin condition, on the face or scalp in adults.
The product is a novel, topical first-in-class microtubule inhibitor with a selective antiproliferative mechanism of action that is claimed to represent a significant step forward in the treatment of actinic keratosis due to its short treatment protocol, one application daily for five days, proven efficacy, and safety profile with very acceptable local tolerability.
The product received approval based on two pivotal phase III studies' (KX01-AK-003 and KX01-AK-004) positive results, published in the New England Journal of Medicine.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT